Undisclosed PRAM (OTC-targeting)

About CAMP4 Therapeutics

CAMP4 Therapeutics is developing a new class of therapeutics that modulate gene expression by targeting the regulatory RNA network, a layer of biology upstream of proteins. The company's platform identifies druggable regRNA nodes to design oligonucleotide-based medicines that can precisely tune gene activity. With a focus on haploinsufficiency diseases, where increasing the output of a single healthy gene copy could provide therapeutic benefit, CAMP4 is building a pipeline with initial programs in CNS and metabolic disorders. The company is backed by leading life science investors and is advancing its lead programs toward clinical development.

Therapeutic Areas

Other Ornithine Transcarbamylase (OTC) Deficiency Drugs